Affirm Holdings, Inc. Share Price Target ‘$36.72’, now 11.2% Upside Potential

DirectorsTalk Interviews

Affirm Holdings, Inc. with ticker code (AFRM) have now 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between $65.00 and $20.00 calculating the mean target share price we have $36.72. (at the time of writing). Now with the previous closing price of $33.03 this now indicates there is a potential upside of 11.2%. Also worth taking note is the 50 day moving average now sits at $33.77 while the 200 day moving average is $31.11. The company has a market capitalization of 9.98B. The stock price is currently at: $32.28 USD

The potential market cap would be $11,093,324,747 based on the market consensus.

The company has a dividend yield of 0.89%. Other points of data to note are a P/E ratio of -, revenue per share of $6.90 and a -5.8% return on assets.

Affirm Holdings, Inc. provides a platform for digital and mobile-first commerce. The Company’s platform comprises three elements: point-of-sale payment solutions for consumers, merchant commerce solutions, and a consumer-focused app. Its point-of-sale solutions allow consumers to pay for purchases in fixed amounts without deferred interest, late fees, or penalties. Its merchant commerce solutions offer commerce enablement, demand generation, and customer acquisition tools. Its consumer-focused app provides Affirm products, which consumers can use to manage payments, open a high-yield savings account, and access a personalized marketplace. The Company’s platform provides consumer and merchant features. Its consumer features include checkout, consumer borrowing, virtual card, affirm app and marketplace and Affirm debit+ card. Its merchant features include affirm at Checkout, merchant dashboard, analytics, client success support, affirm app, and returns management, among others.

Share on:

Latest Company News

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes.

QinetiQ strengthens maritime test positioning as uncrewed naval systems scale

QinetiQ’s expanded underwater testing capacity strengthens its role in the growing market for uncrewed maritime defence systems.

Zotefoams update strengthens the investment case

Zotefoams’ latest update shows a stronger, broader growth business than the current valuation appears to recognise.

Commercial milestones could define Quadrise’s next investment phase

Commercial agreements, project execution and customer adoption remain the key markers investors are likely to watch as Quadrise moves further towards commercial deployment.

Natural hydrogen opens a new investment front in South Australia

Investor interest in natural hydrogen is building as South Australia becomes an early proving ground for exploration, testing and potential commercial development.

Touchstone advances Trinidad output strategy as new wells support cash flow

Touchstone Exploration has brought two Trinidad oil wells into production while advancing gas infrastructure work aimed at improving cash flow, pricing and operational reliability.

    Search